Microglial Depletion, a New Tool in Neuroinflammatory Disorders: Comparison of Pharmacological Inhibitors of the CSF ‐ 1R
Glia · 2025
DOI: 10.1002/glia.24664 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Glia, 2025. Verfasst von David Guenoun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, NeuroDiderot, Université Paris-Cité, Paris, France. Hauptthemen laut MEDLINE: Microglia, Neuroinflammatory Diseases, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Agence Nationale de la Recherche, Fondation de France.
Abstract (Originalsprache)
A growing body of evidence highlights the importance of microglia, the resident immune cells of the CNS, and their pro‐inflammatory activation in the onset of many neurological diseases. Microglial proliferation, differentiation, and survival are highly dependent on the CSF‐1 signaling pathway, which can be pharmacologically modulated by inhibiting its receptor, CSF‐1R. Pharmacological inhibition of CSF‐1R leads to an almost complete microglial depletion whereas treatment arrest allows for subsequent repopulation. Microglial depletion has shown promising results in many animal models of neurodegenerative diseases (Alzheimer's disease (AD), Parkinson's disease, or multiple sclerosis) where transitory microglial depletion reduced neuroinflammation and improved behavioral test results. In this review, we will focus on the comparison of three different pharmacological CSF‐1R inhibitors (PLX3397, PLX5622, and GW2580) regarding microglial depletion. We will also highlight the promising results obtained by microglial depletion strategies in adult models of neurological disorders and argue they could also prove promising in neurodevelopmental diseases associated with microglial activation and neuroinflammation. Finally, we will discuss the lack of knowledge about the effects of these strategies on neurons, astrocytes, and oligodendrocytes in adults and during neurodevelopment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm, NeuroDiderot, Université Paris-Cité, Paris, France.
- Department of Pharmacy, Robert Debré Hospital (AP-HP), Paris, France.
- Department of Anesthesia and Critical Care, Pitié-Salpétrière Hospital (AP-HP), Paris, France.
ORCID-Profile: David Guenoun, Alice Jacquens, Juliette Van Steenwinckel, Pierre Gressens, Cindy Bokobza
Förderung
- Institut National de la Santé et de la Recherche Médicale
- Agence Nationale de la Recherche
- Fondation de France
- Horizon 2020 Framework Programme
- Université Sorbonne Paris Cité
- Fondation des Gueules Cassées
- Assistance Publique - Hôpitaux de Paris
Zitieren
APA
Guenoun, D., Blaise, N., Sellam, A., Roupret-Serzec, J., Jacquens, A., Steenwinckel, J. V., Gressens, P., & Bokobza, C. (2025). Microglial Depletion, a New Tool in Neuroinflammatory Disorders: Comparison of Pharmacological Inhibitors of the CSF ‐ 1R. Glia. https://doi.org/10.1002/glia.24664
Vancouver
Guenoun D, Blaise N, Sellam A, Roupret-Serzec J, Jacquens A, Steenwinckel JV, et al. Microglial Depletion, a New Tool in Neuroinflammatory Disorders: Comparison of Pharmacological Inhibitors of the CSF ‐ 1R. Glia. 2025. doi:10.1002/glia.24664
BibTeX
@article{Guenoun2025,
author = {Guenoun, David and Blaise, Nathan and Sellam, Alexandre and Roupret-Serzec, Julie and Jacquens, Alice and Steenwinckel, Juliette Van and Gressens, Pierre and Bokobza, Cindy},
title = {Microglial Depletion, a New Tool in Neuroinflammatory Disorders: Comparison of Pharmacological Inhibitors of the CSF ‐ 1R},
journal = {Glia},
year = {2025},
doi = {10.1002/glia.24664}
}
EUVIMED